Watch GPCR. Know when insiders buy.
One email the day a filing lands. Free.
GPCR
Structure Therapeutics Inc.
35.50
−3.45 −8.86%
USD · close Sep 16
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
60
WATCH · shorts 60
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $7.6BP/E —DIV YIELD —FCF YIELD -2.96%REV TTM —NET INCOME −$214.8MNET CASH —52W 21.65 – 93.79SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$118.6M | −$106.2M | — | -0.49 | −$120.1M | −$42K | −$120.1M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$89.4M | −$76M | — | -0.35 | $15.2M | $1.2M | $14.1M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | $24M | $33M | — | 0.20 | −$64.4M | $1.5M | −$65.9M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$73.8M | −$65.7M | — | -0.37 | −$51M | $1.6M | −$52.6M | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$70.5M | −$61.7M | — | -0.36 | −$54.6M | $232K | −$54.8M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$56.3M | −$46.8M | — | -0.27 | −$52.2M | $314K | −$52.5M | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$47.1M | −$36.5M | — | -0.22 | −$36.5M | $16K | −$36.5M | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$45.8M | −$34M | — | -0.20 | −$19.7M | $685K | −$20.4M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$33.3M | −$26M | — | -0.18 | −$26.4M | $427K | −$26.8M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$32M | −$26M | — | -0.19 | −$34.1M | $162K | −$34.2M | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$31M | −$24.5M | — | -0.16 | −$21.7M | $1.2M | −$22.9M | Feb 26 |
| Q3 2023 · Sep 30 | — | — | — | −$26.1M | −$23.9M | — | -0.21 | −$20.6M | $820K | −$21.4M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$176.6M | −$141.2M | — | -0.80 | −$222.2M | $3.6M | −$225.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$158.2M | −$122.5M | — | -0.78 | −$116.6M | $1.3M | −$117.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$102.8M | −$89.6M | — | -0.81 | −$79.5M | $2.2M | −$81.7M | — | — |
| FY2022 · to Dec 31 | — | — | −$52.6M | −$51.3M | — | -5.51 | −$46.1M | $155K | −$46.3M | — | — |
Every number comes from Structure Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.